Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales
The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.
You may also be interested in...
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.
Japanese firm points to progress in its cancer pipeline as it looks to launch three new molecular entities in the sector by 2024 and investigates novel modalities.
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.